PART-1
By: pennybuster1 $$$$$
22 Dec 2001, 01:22 AM EST Msg. 944 of 945
ragingbull.lycos.com
The Company 2 Watch........
GMED .08
GenoMed, Inc.
(GMED : Pink Sheets : $0.08)
A Company Focused On Identifying Those Genes Responsible For Causing
Serious Illnesses Such As Diabetes, Kidney Disease & Cancer
GenoMed Has A Proven Track Record Of Genetic Research, Discoveries &
Successful Treatments
We Believe That GMED Knows How To Find Genes Responsible For More Than
80 Common Diseases
CORPORATE INFORMATION
Website: <http://www.Genomedics.com>
Shares O/S: 116,310,000
Public Float: 103,810,000
52-week Range: $0.05 by $0.14
Last Trade: $0.09
Investor Relations: Craig Hall (941-366-6677)
CHall@FloridaFunds.com
ADDITIONAL COMPANY HIGHLIGHTS
GenoMed already owns three potential blockbuster clinical provisional
patents that are ready for immediate licensing.
Scientific data developed by GMED researchers strongly suggests that
GenoMed has identified a class of SNPs that appear to cause more than 80
common diseases.
GMED’s research strategy and methodology has already yielded
discoveries; genomics-based medication can delay or even reverse life-threatening
illnesses such as diabetes, kidney disease and high blood pressure.
Introduction
We’re a lot closer to being able to identify the causes of many major,
debilitating and life-threatening diseases like cancer, diabetes and
kidney disease than most people are probably aware of.
At the forefront of this tremendous advance in medical research is a
newly-listed company: GenoMed, Inc. (OTC : GMED) where researchers are
confident that they are very close to developing DNA-testing and
genomics-based diagnostic methods that will determine who is genetically
"at-risk" for developing many common but serious diseases.
GenoMed believes that it will be successful in its quest to identify
the optimum medications and dosages for treating, arresting, and in many
cases, reversing these life-threatening diseases.
Longer-term, GenoMed’s ultimate goal is to know enough about a person's
genetic predisposition to disease to keep the disease from occurring.
So, is this fiction? Fantasy?
Hardly….
GenoMed’s Chief Medical Officer, Dr. David Moskowitz has demonstrated
the (www.genomedics.com/index…directors), clinical effectiveness of
identifying a disease-associated gene and developing effective treatments
using existing medications.
GenoMed’s Scientists Have Already Developed Genomics-Based Therapies
With Very Positive Initial Results
In 1993, Dr. David Moskowitz, GenoMed’s Chief Medical Officer, first
discovered that angiotensin I-converting enzyme (ACE; drugs against this
enzyme are called "ACE-inhibitors") was a "master" disease gene.
ACE was subsequently found to be associated with about 40 common but
serious diseases such as Type 2 diabetes (and its complications) and
various forms of cancer.
Armed with this knowledge, Dr. Moskowitz subsequently treated his 1,000
patients and achieved some very dramatic results by applying the
concept that diseases can be cured, arrested, or even reversed by modifying
(medicating) the malfunctioning gene(s)..
For example, the rate of progression of kidney disease among Dr.
Moskowitz’s patients due to high blood pressure was reduced by an average of
400% in both African American and Caucasian men.
Through Dr. Moskowitz’s treatment programs, patients expected to reach
dialysis in four years were delayed by an average of 16 years in
reaching end-stage kidney disease.
Patient outcomes for kidney failure due to type 2 diabetes,
atherosclerotic peripheral vascular disease, and emphysema were equally exciting.
Now, having formed GenoMed and raised capital to continue their
research, Dr. Moskowitz and the GMED team will be looking to extend their
success with the ACE "master" disease gene, and fast-tracking the
identification of many, many more disease-causing genes.
Some Background Information On The Science Of Medical Genomics
Genes are the building blocks of life and are responsible for the
production of proteins that make up a cell's structure and operate its vital
chemistry.
Each cell's nucleus holds 46 chromosomes in 23 pairs, containing
approximately 40,000 genes. This set of
genes, the human genome, contains all the instructions for creating a
human being.
The protein products of these genes then carry out those instructions
within every cell of the human body.
The goal of medical genomics is to prevent or cure disease in the
individual patient by exploiting knowledge of these disease-predisposition
genes (see <http://www.genomedics.com/index…science>).
In
In the not too distant future, a routine visit to the doctor will
likely include the extraction of a blood sample from the patient. The
patient’s DNA would then be isolated and analyzed, allowing the physician to
predict the patient’s likelihood of coming down with any of a number of
common chronic diseases during the patient’s lifetime.
Bottom-line, what GenoMed is working on may well result in early
diagnosis of disease and the ability for people to maintain their health,
using safe but extremely <http://www.genomedics.com/index…medicine>)
effective drugs.
GenoMed’s goal is to construct a comprehensive list of disease-causing
genes so that doctors can predict with reasonable confidence what
diseases a person may experience during their lifetime.
GenoMed believes that the place to look for disease-causing mutations
is in the non-coding region of the genes, especially the parts which
determine when the gene is turned on or off (the so-called "regulatory
regions").
Using bio-informatics techniques, the regulatory regions of most of the
40,000 genes can now be deduced using computers. Already-published
variations in regulatory regions can be catalogued, again using computers.
For genes which seem especially important, new variations in their
regulatory regions can be discovered by re-sequencing, a process that
effectively "stretches" DNA by using a number of DNA samples from unrelated
people. |
